We are live on
!
Find out more
iShares US Pharmaceuticals ETF
137 hedge funds and large institutions have $422M invested in iShares US Pharmaceuticals ETF in 2023 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 42 increasing their positions, 27 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
261% more capital invested
Capital invested by funds: $117M → $422M (+$305M)
104.09% more ownership
Funds ownership: 100.18% → 204.27% (+104%)
85% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 13
56% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 27
7% more funds holding
Funds holding: 128 → 137 (+9)
Holders
137
Holders Change
+9
Holders Change %
+7.03%
% of All Funds
2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
24
Increased
42
Reduced
27
Closed
13
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
-$319K
Top Buyers
| 1 |
Fisher Asset Management
Camas,
Washington
|
+$209M |
| 2 |
Morgan Stanley
New York
|
+$55.8M |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.31M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$6.44M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$3.94M |
Top Sellers
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.66M |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$2.29M |
| 3 |
MFG
Merit Financial Group
Alpharetta,
Georgia
|
-$1.84M |
| 4 |
Goldman Sachs
New York
|
-$1.78M |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$1.39M |
